
    
      The treatment will be initiated at the lowest dosage 40 milligrams per day (mg/day), and it
      will be titrated up to 80 mg/day. Patients who are unable to tolerate a dose of at least 80
      mg/day through the end of this study will be discontinued. The dosage will be titrated up to
      a maximum of 120 mg/day.
    
  